King-dom costs Mylan us4 billion

摘要

MAYLAN Laboratories,agreed to acquire troubled drugmaker King Pharmaceuticals Inc for about us4 billion,adding a few branded drugs to Mylan's generic-drug offerings. The deal would help Mylan jump from copycat drugs to more profitable patent protected drugs,a transition that almost every generic drug company aims to make.